X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5748) 5748
Newsletter (155) 155
Book Chapter (38) 38
Newspaper Article (21) 21
Magazine Article (11) 11
Dissertation (10) 10
Publication (5) 5
Book / eBook (3) 3
Conference Proceeding (3) 3
Reference (2) 2
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
warfarin (4385) 4385
humans (4170) 4170
male (2079) 2079
pharmacology & pharmacy (1999) 1999
female (1735) 1735
anticoagulants (1697) 1697
aged (1297) 1297
pharmacokinetics (1262) 1262
middle aged (1258) 1258
anticoagulants - administration & dosage (1210) 1210
anticoagulants - therapeutic use (1182) 1182
drug interactions (1063) 1063
adult (1004) 1004
warfarin - administration & dosage (988) 988
anticoagulants - adverse effects (977) 977
atrial fibrillation (938) 938
warfarin - pharmacokinetics (913) 913
dabigatran (884) 884
administration, oral (868) 868
anticoagulants - pharmacokinetics (848) 848
warfarin - therapeutic use (845) 845
stroke (775) 775
international normalized ratio (761) 761
rivaroxaban (752) 752
hematology (741) 741
warfarin - adverse effects (691) 691
anticoagulation (685) 685
cardiac & cardiovascular systems (632) 632
thromboembolism (617) 617
prevention (601) 601
aged, 80 and over (599) 599
risk factors (599) 599
atrial-fibrillation (594) 594
therapy (587) 587
pharmacogenetics (586) 586
atrial fibrillation - drug therapy (582) 582
analysis (578) 578
peripheral vascular disease (572) 572
animals (566) 566
hemorrhage - chemically induced (556) 556
dose-response relationship, drug (535) 535
cyp2c9 (532) 532
pharmacodynamics (529) 529
research (528) 528
risk (527) 527
drug therapy (515) 515
medicine & public health (506) 506
venous thromboembolism (504) 504
apixaban (497) 497
warfarin - pharmacology (490) 490
metabolism (482) 482
anticoagulants - pharmacology (468) 468
stroke - prevention & control (467) 467
genotype (464) 464
treatment outcome (464) 464
dosage and administration (438) 438
management (435) 435
medicine, general & internal (430) 430
cytochrome p-450 cyp2c9 (425) 425
care and treatment (412) 412
atrial fibrillation - complications (409) 409
pharmacology (401) 401
safety (397) 397
patients (392) 392
thrombosis (388) 388
health aspects (368) 368
bleeding (366) 366
blood coagulation - drug effects (365) 365
aryl hydrocarbon hydroxylases - genetics (355) 355
thrombin (354) 354
cardiac arrhythmia (343) 343
cytochrome p-450 (341) 341
internal medicine (331) 331
abridged index medicus (329) 329
drugs (325) 325
cardiology (322) 322
oral anticoagulants (321) 321
retrospective studies (320) 320
prothrombin time (316) 316
stroke prevention (312) 312
vkorc1 (307) 307
warfarin - blood (306) 306
antithrombotic therapy (304) 304
hemorrhage (299) 299
pharmacology/toxicology (298) 298
drug dosages (297) 297
dabigatran etexilate (286) 286
rats (284) 284
thromboembolism - prevention & control (279) 279
clinical trials (266) 266
warfarin - metabolism (266) 266
time factors (263) 263
usage (256) 256
adolescent (246) 246
algorithms (245) 245
aspirin (244) 244
vitamin k (243) 243
stroke - etiology (242) 242
complications and side effects (241) 241
surgery (239) 239
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5898) 5898
Japanese (68) 68
German (35) 35
French (29) 29
Russian (22) 22
Spanish (15) 15
Portuguese (14) 14
Chinese (8) 8
Czech (6) 6
Turkish (5) 5
Italian (4) 4
Polish (3) 3
Korean (2) 2
Norwegian (2) 2
Swedish (2) 2
Arabic (1) 1
Danish (1) 1
Hungarian (1) 1
Slovenian (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Book
Journal of the American College of Cardiology, ISSN 0735-1097, 2016, Volume 67, Issue 24, pp. 2888 - 2899
... dialysis. The authors review the current pharmacokinetic, observational, and prospective data on NOACs in patients with advanced chronic kidney disease... 
Cardiovascular | Internal Medicine | dabigatran | rivaroxaban | apixaban | stroke | edoxaban | renal dialysis | CARDIAC & CARDIOVASCULAR SYSTEMS | APPENDAGE CLOSURE | PLATELET-AGGREGATION | SAFETY | PHARMACOKINETICS | PROTHROMBIN COMPLEX CONCENTRATE | ORAL ANTICOAGULANTS | HEMODIALYSIS-PATIENTS | NONVALVULAR ATRIAL-FIBRILLATION | STAGE RENAL-DISEASE | WARFARIN USE | Pyrazoles - therapeutic use | Dabigatran - pharmacokinetics | Humans | Pyridines - pharmacokinetics | Renal Insufficiency, Chronic - complications | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Thiazoles - pharmacokinetics | Warfarin - therapeutic use | Renal Insufficiency, Chronic - therapy | Kidney - metabolism | Pyrazoles - pharmacokinetics | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Stroke - prevention & control | Glomerular Filtration Rate | Pyridones - pharmacokinetics | Atrial Fibrillation - drug therapy | Anticoagulants - therapeutic use | Creatinine - urine | Warfarin - pharmacokinetics | Kidney Failure, Chronic - therapy | Rivaroxaban - pharmacokinetics | Kidney Failure, Chronic - complications | Anticoagulants - pharmacokinetics | Pyridones - therapeutic use | Hemorrhage - chemically induced | Renal Dialysis | Stroke (Disease) | Medical colleges | Care and treatment | Continuing medical education | Warfarin | Chronic kidney failure | Atrial fibrillation | Mortality | Medical care | Quality management | Urine | Confidence intervals | Disease prevention | Anticoagulants | Stroke | Hemodialysis | Kidney diseases | Metabolism | Drug dosages
Journal Article
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 2001, Volume 40, Issue 2, pp. 85 - 104
Journal Article
Advances in Therapy, ISSN 0741-238X, 2/2012, Volume 29, Issue 2, pp. 163 - 177
...). The aim of these studies was to assess the potential for pharmacokinetic interaction between dapagliflozin, a sodium glucose co-transporter-2 inhibitor being developed for the treatment of T2DM... 
dapagliflozin | pharmacodynamics | Rheumatology | simvastatin | sodium glucose co-transporter-2 | Internal Medicine | Oncology | digoxin | warfarin | type 2 diabetes | Medicine & Public Health | pharmacokinetics | valsartan | Cardiology | Pharmacology/Toxicology | Endocrinology | MEDICINE, RESEARCH & EXPERIMENTAL | SELECTIVE SGLT2 INHIBITOR | HEALTHY-SUBJECTS | HUMANS | INADEQUATE GLYCEMIC CONTROL | DIABETES-MELLITUS | POTENT | HYPERGLYCEMIA | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | TYPE-2 | ASSOCIATION | Hypoglycemic Agents - pharmacokinetics | Benzhydryl Compounds | Valsartan | Valine - pharmacokinetics | Humans | Middle Aged | Valine - analogs & derivatives | Male | Glucosides - pharmacokinetics | Antihypertensive Agents - pharmacokinetics | Simvastatin - pharmacokinetics | Anti-Arrhythmia Agents - pharmacokinetics | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Digoxin - pharmacokinetics | Warfarin - pharmacokinetics | Cross-Over Studies | Anticholesteremic Agents - pharmacokinetics | Drug Interactions | Adult | Female | Anticoagulants - pharmacokinetics | Diabetes Mellitus, Type 2 - drug therapy | Tetrazoles - pharmacokinetics | Type 2 diabetes | Warfarin | Digoxin | Simvastatin | Drug interactions | Anticoagulants (Medicine) | Glucose | Dextrose | Antilipemic agents | Cardiac glycosides | Blood circulation disorders | Cardiotonic agents | Cardiac patients | Diabetes | Heart diseases
Journal Article
Canadian journal of cardiology, ISSN 0828-282X, 2013, Volume 29, Issue 7, pp. S24 - S33
... variability in response, unpredictable pharmacokinetic characteristics (PK), drug-drug interactions, and polymorphisms in genes affecting metabolism and pharmacodynamic... 
Cardiovascular | IN-VITRO | CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT THROMBIN INHIBITOR | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | VENOUS THROMBOEMBOLISM | STROKE PREVENTION | ASSAYS LABORATORY RECOMMENDATIONS | ORAL BIOAVAILABILITY | NONVALVULAR ATRIAL-FIBRILLATION | COAGULATION ASSAYS | Anticoagulants - administration & dosage | Outcome Assessment (Health Care) | Thiophenes - adverse effects | Humans | beta-Alanine - pharmacokinetics | Warfarin - adverse effects | Biological Availability | Thiophenes - administration & dosage | Dabigatran | Drug Monitoring - methods | Warfarin - administration & dosage | Patient Selection | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Drug Interactions | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Pyrazoles - pharmacokinetics | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Pyrazoles - adverse effects | Stroke - prevention & control | beta-Alanine - adverse effects | Pyridones - pharmacokinetics | Administration, Oral | Atrial Fibrillation - drug therapy | Morpholines - administration & dosage | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | Benzimidazoles - pharmacokinetics | Anticoagulants - adverse effects | Polymorphism, Genetic | Warfarin - pharmacokinetics | Atrial Fibrillation - blood | Thiophenes - pharmacokinetics | Pyrazoles - administration & dosage | Stroke - etiology | Blood Coagulation - drug effects | Blood Coagulation - genetics | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Pyridones - adverse effects
Journal Article